ACC 2016: Novartis' Entresto reduces risk of hospitalization in HF patients

The data will likely help Novartis as it builds out recent pay-for-performance deals with Aetna and Cigna, two major insurers. 

By Nicole Gray • April 3, 2016

Lilly's arthritis drug baricitinib notches another success

The drug will have significant competition however, as a number of companies are also lining up new rheumatoid arthritis treatments. 

By Nicole Gray • April 1, 2016

Explore the Trendline➔

Neuroscience drug development

Enthusiasm is running higher among drugmakers and investors for neuroscience drug development, buoyed by recent approvals of new Alzheimer’s, ALS and depression medicines.

By BioPharma Dive staff

FDA panel says benefits outweigh risks for Acadia's Parkinson's drug

The advisory committee voted 12-2 in favor of the Parkinson's disease psychosis drug, setting the stage for a FDA decision May 1. 

By Ned Pagliarulo • March 29, 2016

Theranos blood testing inconsistent with other labs, study shows

Compared to testing by LabCorp and Quest Diagnostics, Theranos' technology was 1.6 times more likely to yield abnormal results.

By Nicole Gray • March 29, 2016

New phase 2 data boosts prospects for Alder's migraine drug

The company hopes to stay abreast of competing companies, such as Amgen and Lilly, which are developing drugs using the same mechanism as Alder's ALD403. 

By Ned Pagliarulo • March 28, 2016

New poll finds widespread support for cancer research funding

According to the STAT-Harvard poll, over 80% of Americans believe a 20% increase in federal research funding would be appropriate or not enough. 

By Nicole Gray • March 28, 2016

Amid safety concerns, FDA adcomm set to review Acadia's Parkinson's drug

Acadia's Nuplazid is forecast for over $1 billion in 2020 sales, but has to clear regulatory hurdles in Tuesday's advisory committee review. 

By Nicole Gray • March 28, 2016

In major stroke study, AstraZeneca's Brilinta fails to beat aspirin

The global trial measured the reduction in recurrent events after a patient first suffers a stroke. 

By Ned Pagliarulo • March 23, 2016

BioMarin's PKU drug meets primary goal in phase 3, but falls short on secondary endpoints

The company hopes to file for approval with the FDA by the end of the year. 

By Nicole Gray • March 22, 2016

Biden names corporate exec Greg Simon to lead Cancer Moonshot

Simon has previously worked with the charity FasterCures, as well as at Pfizer and as CEO of the life sciences finance company Poliwogg. 

By Nicole Gray • March 21, 2016

Johnson & Johnson's psoriasis drug Stelara succeeds in Phase 3

The blockbuster treatment proved effective against a placebo in treating Crohn's disease. 

By Ned Pagliarulo • March 18, 2016

In new deal, Kite Pharma partnering with Roche on cancer immunotherapy

The collaboration will explore combining Kite's leading CAR-T therapy with Roche's atezolizumab. 

By Ned Pagliarulo • March 18, 2016

Top Gilead cancer researcher has left company

The news of the departure comes as Gilead has halted six trials for its cancer drug Zydelig after an increased number of adverse events.

By Nicole Gray • March 18, 2016

In limited study, NIH-developed dengue vaccine proves 100% effective

Researchers hope their work can help inform development of a vaccine for Zika virus, which shares similarities with dengue. 

By Nicole Gray • March 17, 2016

EMA finalizes clinical trial redaction guidelines

Pharmaceutical companies claim publication of all clinical trial data would compromise trade secrets. Advocates for transparency, on the other hand, argue more information is need to enhance the ability to replicate important findings. 

By Nicole Gray • March 16, 2016

Lilly changes endpoint for phase 3 Alzheimer's trial

The endpoint change for solanezumab will affect data analysis, but not the actual conduct of the trial. 

By Nicole Gray • March 16, 2016

As EMA investigates, Gilead halts six clinical trials of cancer drug

Gilead has been working to expand the indications of Zydelig, hoping to break into oncology.

By Ned Pagliarulo • March 15, 2016

Roche signs potential $1 billion cancer immunotherapy deal with Cambridge biotech

Separately, the FDA boosted the prospects of Roche's bladder cancer drug atezolizumab, granting the immunotherapy priority review status. 

By Ned Pagliarulo • March 15, 2016

GW Pharma stock doubles after positive phase 3 cannabis drug results

In a trial involving 120 patients, treatment with Epidiolex resulted in a median 39% reduction in seizures, compared with 13% in placebo-treated patients. 

By Nicole Gray • March 15, 2016

EU regulators investigating Gilead's Zydelig after infection deaths

Higher rates of adverse events were seen in three clinical trials involving Zydelig and other cancer drugs. 

By Nicole Gray • March 14, 2016

Sanofi's sarilumab bests blockbuster Humira in Phase 3 study

The IL-6 antibody is slated for a regulatory decision from the FDA by Q4 2016. 

By Ned Pagliarulo • March 11, 2016

Death from French drug trial likely due to high doses of compound

The drug trial left one man dead and five others in the hospital in January. Portuguese drugmaker Bial had been testing an FAAH-enzyme inhibitor for the treatment of pain and mood disorders. 

By Ned Pagliarulo • March 10, 2016

French regulator halts manufacturing at HIV-focused biotech

A November inspection by ANSM turned up 45 manufacturing deficiencies, including five critical flaws. 

By Nicole Gray • March 10, 2016

Novartis' Cosentyx proves superior to Janssen's Stelara in head-to-head comparison

The efficacy data further bolsters the profile of Cosentyx, which recently had its label expanded to include indications for ankylosing spondylitis and psoriatic arthritis.

By Nicole Gray • March 7, 2016

In high-profile failure, Celldex's cancer vaccine crashes in phase 3

The biotech ended its study early after an interim analysis showed patients treated with the gliobastoma drug fared slightly worse than the control group.

By Ned Pagliarulo • March 7, 2016